MASLD, metabolic dysfunction-associated steatotic liver disease; T2D, type 2 diabetes; BMI, body mass index; LFTs, liver function tests; FLI, fatty liver index; LSM, liver stiffness measurement; CA, chlorogenic acid; CI, confidence interval; CAP, controlled attenuation parameter; CK-18, cytokeratin 18; AST, aspartate aminotransferase; ALT, alanine transaminase; GGT, γ-glutamyl transferase; mTOR, mammalian target of rapamycin; N/A: not applicable/available. This evidence concerns the gene KRT18 and type 2 diabetes mellitus.